B7-H4 Antibody, anti-mouse, REAfinity™
Synonyms: Vtcn1, B7h4, B7S1, B7x, BC032925
RECOMBINANT
Clone:
REA392 | HMH4-5G1
Type of antibody:
Primary antibodies, Recombinant antibodies
Isotype:
recombinant human IgG1
Applications:
FC Glossary
External link icon
Quality Assurance Certified ProductSatisfaction
guaranteed
more »
Select a conjugate:
Select a size:
Other sizes

Related products for B7-H4 Antibody, anti-mouse, REAfinity™

Flow cytometry applications
APC
Biotin
PE
PE-Vio 770
Vio Bright FITC
Recommended dilution:
1:10
Remark:
Cells should be stained prior to fixation, if formaldehyde is used as a fixative.
Data source:
Miltenyi Biotec
Conjugate:
APC
Used products:
130-106-340, 130-106-413
Description:
Latex beads were coated with recombinant mouse B7-H4 protein and then stained with Anti-B7-H4 antibodies or with the corresponding REA control (S) antibodies (left peak). Flow cytometry was performed with the MACSQuant® Analyzer.

Application image
Species tested:
mouse
Recommended dilution:
1:50
Remark:
Cells should be stained prior to fixation, if formaldehyde is used as a fixative.
Data source:
Miltenyi Biotec
Conjugate:
APC
Used products:
130-140-214
Description:
Latex beads were coated with recombinant mouse B7-H4 protein and then stained with Anti-B7-H4 antibodies or with the corresponding REA control (S) antibodies (left peak). Flow cytometry was performed with the MACSQuant® Analyzer.

Application image
Specifications for B7-H4 Antibody, anti-mouse, REAfinity™
Overview

Clone REA392 recognizes the mouse B7-H4 antigen, a glycosylphosphatidylinositol (GPI) linked protein which is also known as V-set domain containing T-cell activation inhibitor 1 (Vtcn1). The B7 family of T cell costimulatory and coinhibitory molecules plays a pivotal role in the regulation of adaptive immune responses. As such, B7-H4 was identified as a coinhibitory member of the B7 family. In mice, B7-H4 expression is limited to B cells and APCs. B7-H4 negatively regulates T-cell-mediated immune response by inhibiting T-cell activation, proliferation, cytokine production and development of cytotoxicity. It has also been shown to negatively regulate neutrophil-mediated innate immune responses. Apart from the immune system, B7-H4 is overexpressed on some tumor cancer cells. When expressed on the cell surface of tumor macrophages, B7-H4 plays an important role, together with regulatory T-cells, in the suppression of tumor-associated antigen-specific T-cell immunity.

Additional information: Clone REA392 displays negligible binding to Fc receptors.

Alternative names

Vtcn1, B7h4, B7S1, B7x, BC032925

Detailed product information

Technical specifications

Clone
REA392
Clonality
monoclonal
Isotype
recombinant human IgG1
Isotype control
REA Control Antibody, human IgG1
Host
human cell line
Type of antibody
Primary antibodies, Recombinant antibodies
Species reactivity
mouse
Antigen
B7-H4
Molecular mass of antigen [kDa]
26
Distribution of antigen
B cells, monocytes, dendritic cells, macrophages
Entrez Gene ID
RRID
AB_2651247, AB_2651250, AB_2651244, AB_2651251, AB_2651252, AB_2651253, AB_2651246, AB_2651245, AB_2651248, AB_2651249

Recombinant antibodies at Miltenyi Biotec

As an innovation-powered company with a commitment to quality and excellence, Miltenyi Biotec applies cutting-edge methods to discover and develop newer and better antibodies to satisfy both market demand and regulatory requirements.

The Miltenyi way of generating best-in-class antibodies and antibody conjugates

At Miltenyi Biotec, we opt for recombinant antibodies, which enable sequence verification and optimization for lot-to-lot consistency, making them superior to hybridoma-based antibodies.

Infusing our unique expertise

Recombinants are the result of combining genetic material from different immunized animals, and using display technologies to screen in-house antibody libraries for the best antibodies. Additional analyses on existing hybridoma-based antibodies can also give rise to sequences contributing to novel recombinants.

Maximizing value for your research

By further re-engineering these antibody sequences, we can precisely control their properties to achieve the following benefits:

reduce undesirable binding to Fc gamma receptors,

  • eliminate destabilizing amino acid motifs,
  • increase specific bonding affinity for stronger, more accurate targeting, and
  • optimize fluorochrome conjugation for brighter and clearer signals.

In a final step, by synthesizing and cloning the resulting gene sequence, we achieve an expression vector that develops a cell line, which in turn produces a special recombinant antibody.

Better science with quality antibodies

Already in 2015, 100 of the world’s leading scientists collectively called for better standards and reproducibility in antibody production, proposing recombinant antibodies to circumvent variability (Baker, M. Reproducibility crisis: Blame it on the antibodies. Nature 521, 274–276 (2015). https://doi.org/10.1038/521274a). Moreover, by applying reverse engineering, which is encouraged by the EU Directive 2016/943 r, Miltenyi Biotec acts “[i]n the interest of innovation and fostering competition…” (§16).

Resources for B7-H4 Antibody, anti-mouse, REAfinity™
Certificates

To access a Certificate of Analysis (CoA) follow the link below and enter the specific lot of your product.

Get certificate

Should you wish to request additional documentation, such as a Safety Data Sheet (SDS) in other languages than English or Swedish, an SDS-replacement document, or a Certificate of Origin (CoO), please direct your inquiry to your local technical support team.

Contact technical support

Citations for B7-H4 Antibody, anti-mouse, REAfinity™
Publications
  1. Sica, G. L. et al. (2003) B7-H4, a molecule of the B7 family, negatively regulates T cell immunity. Immunity 18 (6): 849-861
  2. Zhu, G. et al. (2009) B7-H4-deficient mice display augmented neutrophil-mediated innate immunity. Blood 113 (8): 1759-1767
  3. Leung, J. et al. (2013) Host B7-H4 regulates antitumor T cell responses through inhibition of myeloid-derived suppressor cells in a 4T1 tumor transplantation model. J Immunol 190 (12): 6651-6661

You have previously chosen International as your location.
What do you want to do?